Is Apollomics Inc. (APLM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.2% / 30% | 22.7% / 30% | 0.3% / 30% | N/A | ✓ HALAL |
| DJIM | 2.2% / 33% | 22.7% / 33% | 0.3% / 33% | N/A | ✓ HALAL |
| MSCI | 7.4% / 33% | 74.6% / 33% | 1.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.2% / 33% | 22.7% / 33% | 0.3% / 33% | N/A | ✓ HALAL |
| FTSE | 7.4% / 33% | 74.6% / 33% | 1.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -124.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -380.1% | |
| Return on Assets (ROA) | -72.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$29M |
| Free Cash Flow | -$29M |
| Total Debt | $966,000 |
| Current Ratio | 1.0 |
| Total Assets | $13M |
Price & Trading
| Last Close | $17.62 |
| 50-Day MA | $19.47 |
| 200-Day MA | $14.63 |
| Avg Volume | 14K |
| Beta | 1.8 |
|
52-Week Range
$3.66
| |
About Apollomics Inc. (APLM)
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Apollomics Inc. (APLM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Apollomics Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Apollomics Inc.'s debt ratio?
Apollomics Inc.'s debt ratio is 2.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.4%.
What are Apollomics Inc.'s key financial metrics?
Apollomics Inc. has a market capitalization of $37M. Return on equity stands at -380.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.